Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database

Br J Haematol. 2022 Oct;199(2):256-259. doi: 10.1111/bjh.18381. Epub 2022 Jul 28.

Abstract

Acute myeloid leukaemia (AML) is conventionally thought of as a medical emergency. However, several studies on the association of time from diagnosis to treatment with survival did not have concordant results. Here we analyse 55 985 AML patients from the National Cancer Database, and we show that in patients less than 60 years old a five-day delay in chemotherapy initiation leads to worse long-term survival. The difference is small [hazard ratio (HR) 1.05, 95% confidence interval (CI) 1.01-1.09 in multivariate analysis] but statistically significant. This study raises the issue of power to detect small differences in retrospective studies.

Keywords: acute myeloid leukaemia; time from diagnosis to treatment; time to treatment.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Databases, Factual
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / mortality
  • Leukemia, Myeloid, Acute* / therapy
  • Middle Aged
  • Proportional Hazards Models
  • Retrospective Studies
  • Survival Analysis
  • Time-to-Treatment* / statistics & numerical data
  • United Kingdom / epidemiology